Investors tend to turn to big blue-chip dividend payers at times of market volatility, and in times past the steady earnings of pharma giants GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) have been a particular source of comfort when the market is falling. But in the recent lurch lower, Londons biggest drugs companies did just as badly as the FTSE 100. How come?
If you’re interested in backing UK companies with exciting growth potential, then you’ll want to read ourlatest FREE report. Simply click through to discover our analysts’number one growth stock for 2014!
Owain Bennallackowns shares in GSK and AZN. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.